Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections

Current Opinion in Infectious Diseases

Volumn 24, Issue 3, 2011, Pages 241-247

  Calbo, Esther ^a,b   Garau, Javier ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

innate immune system; pneumococcal virulence factors; Streptococcus pneumonia; systemic inflammatory response syndrome

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CELL SURFACE PROTEIN; CORTICOSTEROID; DEXAMETHASONE; IMMUNOMODULATING AGENT; LEVOFLOXACIN; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VIRULENCE FACTOR;

AGE DISTRIBUTION; ARTICLE; BACTEREMIA; BACTERIUM PILUS; COMORBIDITY; CORTICOSTEROID THERAPY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 79955523237     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283463e45     Document Type: Article

References (77)

1. Van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374:1543-1556.
2. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008; 358:716-727.
3. Calbo E, Garau J. Of mice and men: innate immunity in pneumococcal pneumonia. Int J Antimicrob Agents 2010; 35:107-113.
4. Austrian R, Gold J. Pneumococcal bacteraemia with especial reference to bacteraemic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-776.
5. Brouwer MC, de Gans J, Heckenberg SG, et al. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and metaanalysis. Lancet Infect Dis 2009; 9:31-44.
6. Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or ?immuno-fairy? tales? Clin Microbiol Rev 2000; 3:615-650.
7. Dalhoff A, Shalit I. Immunomodulatory effect of quinolones. Lancet Infect Dis 2003; 3:359-371.
8. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995; 33:2759-2762.
9. Täuber MG, Burroughs M, Niemöller UM, et al. Differences of pathophysiology in experimental meningitis caused by three strains of Streptococcus pneumoniae. J Infect Dis 1991; 163:806-811.
10. Engelhard D, Pomeranz S, Gallily R, et al. Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J Infect Dis 1997; 175:979-982. (Pubitemid 27142982)
11. Ostergaard C, Brandt C, Konradsen HB, Samuelsson S. Differences in survival, brain damage, and cerebrospinal fluid cytokine kinetics due to meningitis caused by 3 different Streptococcus pneumoniae serotypes: evaluation in humans and in 2 experimental models. J Infect Dis 2004; 190:1212-1220. (Pubitemid 39287746)
12. Jagger MP, Huo Z, Riches PG. Inflammatory cytokine (interleukin 6 and tumour necrosis factor alpha) release in a human whole blood system in response to Streptococcus pneumoniae serotype 14 and its capsular polysaccharide. Clin Exp Immunol 2002; 130:467-474. (Pubitemid 35418330)
13. Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 1987; 135:869-874. (Pubitemid 17055516)
14. Hyams C, Yuste J, Bax K, et al. Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype. Infect Immun 2010; 78:716-725.
15. Melin M, Trzciński K, Meri S, et al. The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun 2010; 78:5262-5270.
16. Ribes S, Taberner F, Cabellos C, et al. Contribution of capsular and clonal types and beta-lactam resistance to the severity of experimental pneumococcal meningitis. Microbes Infect 2008; 10:129-134.
17. Sandgren A, Albiger B, Orihuela CJ, et al. Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans. J Infect Dis 2005; 192:791-800. (Pubitemid 41193076)
18. Garcia-Vidal C, Ardanuy C, Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax 2010; 65:77-81.
19. Pettigrew MM, Fennie KP, York MP, et al. Variation in the presence of neuraminidase genes among Streptococcus pneumoniae isolates with identical sequence types. Infect Immun 2006; 74:3360-3365. (Pubitemid 43794525)
20. Kadioglu A, Taylor S, Iannelli F, et al. Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect Immun 2002; 70:2886-2890. (Pubitemid 34564145)
21. Thornton JA, Durick-Eder K, Tuomanen EI. Pneumococcal pathogenesis: ?innate invasion? yet organ-specific damage. J Mol Med 2010; 88:103-107.
22. Alanee SR, McGee L, Jackson D, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007; 45:46-51. (Pubitemid 46984614)
23. Sjostrom K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as primary or opportunistic pathogens. Clin Infect Dis 2006; 42:451-459. (Pubitemid 43202515)
24. Berg S, Trollfors B, Persson E, et al. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 2006; 38:427-432. (Pubitemid 44150775)
25. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6:e1000.
26. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49:e23-e29.
27. Luján M, Gallego M, Belmonte Y, et al. Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 2010; 36:1073-1079.
28. Martens P, Worm SW, Lundgren B, et al. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis 2004; 4:21-28.
29. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692-699.
30. Orihuela CJ, Radin JN, Sublett JE, et al. Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun 2004; 72:5582-5596. (Pubitemid 39303666)
31. Oggioni MR, Trappetti C, Kadioglu A, et al. Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol Microbiol 2006; 61:1196-1210. (Pubitemid 44215421)
32. Molzen TE, Burghout P, Bootsma HJ, et al. Genome-wide identification of Streptococcus pneumoniae genes essential for bacterial replication during experimental meningitis. Infect Immun 2011; 79:288-297.
33. Hausdorff W, Fiekin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5:83-93. (Pubitemid 40174779)
34. Canvin JR, Marvin AP, Sivakumaran M, et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 1995; 172:119-123.
35. Price KE, Camilli A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol 2009; 191:2163-2168.
36. Hirst RA, Kadioglu A, O?Callaghan, Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol 2004; 138:195-201. (Pubitemid 39472433)
37. McNeela EA, Burke A, Neill DR, et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 2010; 6:e1001191.
38. Shoma S, Tsuchiya K, Kawamura I, et al. Critical involvement of pneumolysin in production of interleukin-1alpha and caspase-1-dependent cytokines in infection with Streptococcus pneumoniae in vitro: a novel function of pneumolysin in caspase-1 activation. Infect Immun 2008; 76:1547-1557. (Pubitemid 351561998)
39. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008; 6:288-301. (Pubitemid 351404773)
40. Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 2001; 183:827-830. (Pubitemid 32171761)
41. Spreer A, Kerstan H, Böttcher T, et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003; 47:2649-2654. (Pubitemid 36919474)
42. Bermpohl D, Halle A, Freyer D, et al. Bacterial programmed cell death of cerebral endothelial cells involves dual death pathways. J Clin Invest 2005; 115:1607-1615. (Pubitemid 40814669)
43. Wellmer A, Zysk G, Gerber J, et al. Decreased virulence of a pneumolysindeficient strain of Streptococcus pneumoniae in murine meningitis. Infect Immun 2002; 70:6504-6508. (Pubitemid 35192751)
44. Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A 2006; 103:2857-2862.
45. Aguiar SI, Serrano I, Pinto FR, et al. The presence of the pilus locus is a clonal property among pneumococcal invasive isolates. BMC Microbiol 2008; 8:41.
46. Moschioni M, Donati C, Muzzi A, et al. Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis 2008; 197:888-896. (Pubitemid 351417013)
47. Brandt CT, Holm D, Liptrot M, et al. Impact of bacteremia on the pathogenesis of experimental pneumococcal meningitis. J Infect Dis 2008; 197:235-244. (Pubitemid 351263442)
48. Garcia-Vidal C, Fernández-SabéN, CarratalàJ, et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 2008; 32:733-739.
49. Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009; 136:832-840.
50. Otero J, Alós JI, Gómez-Garcés JL. Antimicrobial resistance of Streptococcus pneumoniae in 1999-2000 in Madrid (Spain): multicenter surveillance study J Antimicrob Chemother 2001; 47:215-218. (Pubitemid 32149532)
51. Azoulay-Dupuis E, Rieux V, Muffat-Joly M, et al. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 2000; 44:1575-1577. (Pubitemid 30340797)
52. Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42:788-797. (Pubitemid 43363934)
53. Bruunsgaard H, Skinhoj P, Qvist J, Pedersen BK. Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections. J Infect Dis 1999; 180:551-554. (Pubitemid 30256347)
54. Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994; 150:710-716. (Pubitemid 24291499)
55. Calbo E, Valdés E, Ochoa de Echagüen A, et al. Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected. Eur J Clin Microbiol Infect Dis 2009; 28:971-976.
56. Calbo E, Alsina M, Rodríguez-Carballeira M, et al. The impact of time on the systemic inflammatory response in pneumococcal pneumonia. Eur Respir J 2010; 35:614-618.
57. Khor C, Chapman S, Vannberg FO, et al. AMalfunctional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523-528. (Pubitemid 46514767)
58. Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK 4 deficient children: IRAK 4 dependent TLR are otherwise redundant in protective immunity. J Exp Med 2007; 204:2407-2422. (Pubitemid 47529326)
59. Chapman SJ, Khor CC, Vannberg FO, et al. Common NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association study. Crit Care 2010; 14:R227.
60. Chapman SJ, Khor CC, Vannberg FO, et al. NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations. Genes Immun 2010; 11:319-325.
61. Yuan FF, Marks K, Wong M, et al. Clinical relevance of TLR2, TLR4, CD14 and Fc gamma RIIA gene polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol 2008; 86:268-270. (Pubitemid 351430807)
62. Chapman SJ, Khor CC, Vannberg FO, et al. PTPN22 and invasive bacterial disease. Nat Genet 2006; 38:499-500.
63. Schaaf B, Rup J, Müller-Stinhardt M, et al. The interleukin 6 -174 promoter polymorphism is associated with extrapulmonary bacterial dissemination in Streptococcus pneumoniae infection. Cytokine 2005; 31:324-328. (Pubitemid 41097369)
64. Waterer G, Quasney MW, Cantor R, Wunderink RC. Septic shock and respiratory failure in community acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163:1599-1602.
65. Wunderink RC, Waterer GW, Cantro RM, Quasney M. Tumor necorsis factor gene polymorphisms and the variable presentation and outcome of community- acquired pneumonia. Chest 2002; 121:S87.
66. Gallagher PM, Lowe G, Fitzgerald T, et al. Association of IL 10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003; 58:154-156. (Pubitemid 36183005)
67. Schaaf B, Boehmke F, Esnaashari H, et al. Pneumococcal septic shock is associated with the interleukin 10 -1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003; 168:476-480. (Pubitemid 37046878)
68. Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2010; 2:114-122.
69. Roy S, Hill AVS, Know K, et al. Association of common genetic variants with susceptibility to invasive pneumococcal disease. BMJ 2002; 324: 1369. (Pubitemid 34628009)
70. Eisen DP, Dean MM, Boermeester MA, et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis 2008; 47:510-516.
71. Calbo E, Alsina M, Rodríguez-Carballeira M, et al. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008; 52:2395-2402. (Pubitemid 351915668)
72. Padrones S, Garcia-Vidal C, Fernández-Serrano S, et al. Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2010; 29:1243-1251.
73. Spreer A, Lugert R, Stoltefaut V, et al. Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit Care Med 2009; 37:2253-2258.
74. Grandgirard D, Oberson K, Bühlmann A, et al. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2010; 54:1323-1326.
75. Van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010; 9:254-263.
76. Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010:CD004405.
77. Brouwer MC, Heckenberg SG, de Gans J, et al. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010; 75:1533-1539.